Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Lumos Pharma, Inc.

Lumos Pharma and Double Point Ventures Announce Successful Completion of Tender Offer and Double Point Ventures’ Acquisition of Lumos Pharma
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Two Abstracts Accepted for Oral Presentation at the 62ⁿᵈ Annual ESPE Meeting 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Enters into Definitive Merger Agreement with Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Abstract Accepted for Presentation at September Medical Meeting, SLEP 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Participate in H.C. Wainwright 26th Annual Global Investment Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Reports Second Quarter 2024 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Report Second Quarter 2024 Financial Results and Provide Clinical Update on August 1, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Abstracts Accepted for Presentation at ENDO 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Positive End-of-Phase 2 Meeting with FDA and Reports First Quarter 2024 Financial Results
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Report First Quarter 2024 Financial Results and Provide Clinical Update on May 15, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces that the USPTO Has Granted Patent Protection for Novel Formulation of LUM-201, Extending Exclusivity to 2042
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Reports Full Year 2023 Financial Results and Provides Clinical Development Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Report Full Year 2023 Financial Results and Host Conference Call on March 7, 2024
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Participate in Oppenheimer’s 34th Annual Healthcare Life Sciences Conference
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Promotes Pisit “Duke” Pitukcheewanont, MD to Chief Medical Officer
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Host Virtual Key Opinion Leader Webinar to Discuss Phase 2 OraGrowtH Trial Data and Treatment Potential of Oral LUM-201 for Pediatric Growth Hormone Deficiency
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Participation in the Piper Sandler 35th Annual Healthcare Conference in November
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Reports Third Quarter 2023 Financial Results and Clinical Development Updates
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Topline Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials of LUM-201 in PGHD Met All Primary and Secondary Endpoints
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces New Data and Analysis of 15 Subjects from OraGrowtH212 Trial Presented at the 2023 ESPE Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announced Abstract Accepted for Oral Presentation at the European Society for Paediatric Endocrinology Annual Meeting
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Announces Participation in Investor Conferences in September
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Independent Panel of Renowned Pediatric Endocrinologists to Discuss Pediatric Growth Hormone Deficiency and the Therapeutic Landscape
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma Reports Second Quarter 2023 Financial Results, Provides Clinical Update
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Lumos Pharma to Participate in the Oppenheimer 2023 Montauk Life Sciences Summit
From Lumos Pharma, Inc.
Via GlobeNewswire
Tickers LUMO
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.